Lilly presented Phase 1 data for AJ1-11095, a type II JAK2 inhibitor in development for myelofibrosis, at EHA in Stockholm. The update follows Lilly’s acquisition of Ajax Therapeutics, which supplied the program. The presentation adds early clinical evidence to a crowded myelofibrosis landscape where JAK inhibition is foundational but durability and disease control remain key differentiators. Investors will focus on safety/tolerability signals and whether AJ1-11095 shows any pathway toward improved depth of response versus existing options. EHA also served as a stage for broader blood-cancer competitive dynamics as Lilly seeks to translate acquired pipeline assets into next-gen differentiation.